Drug intelligence / Profile preview

SHD001

Development stage: Unknown
Lead developer: Shihuida Pharmaceutical Group
Administration: Topical

Overview

SHD001 is a biological drug candidate currently under development by Shihuida Pharmaceutical Group. It is designed for topical administration to treat various dermatological conditions. As of early 2024, the candidate is in Phase 1 clinical development. While it is categorized as a biological product in the company's pipeline, specific details regarding its molecular target, mechanism of action, or the exact skin conditions it aims to treat have not been publicly disclosed.

Beyond the preview

Go deeper on SHD001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SHD001.

Explore the full profile